**ACC7984**
**Pain Management Services Triage Report**
Please complete this form to let us know about this client's triage assessment, the conclusions regarding the likely diagnosis/es and cause/s and the proposed clinical care pathway.
When you've finished, please send a copy to the ACC recovery team member managing the Claim or to claims@acc.co.nz if you are unsure of the Recovery Team Member/Recovery Team.
**1. Client details**
Client name: Hemi Walker
Address: 47 Tāwā Road, Glen Eden, Auckland 0602
Claim number: 10068472
Date of birth: 22/06/1979
**2. Vendor details**
Supplier name: Tāmaki Pain Service
Vendor number: PMC8847
Phone number: 09 631 4422
Vendor email address: triage@tamakipain.co.nz
**3. Confirmation of suitability for the Pain Management Service**
**Recommendation:**
Note: Choose Group Programme when required, and/or one of the following Community Level 1, Community Level 2 or Tertiary if required
Rationale for any recommended Pain Management Service is provided in the Summary of Findings in Section 4.
[ ] Not suitable for a Pain Management service (see below)
[ ] Group Programme
[ ] Community Services Level 1
[x] Community Services Level 2
[ ] Tertiary Delivery Services
If the client is not suitable for the Pain Management Service, please explain why and any recommendations on what support or alternative service the client needs:
For clients who are recommended for the Pain Management Service, do they meet the eligibility criteria?
[ ] Not applicable, the Pain Management Service is not recommended
[x] Yes, the client meets the eligibility criteria for the recommended Pain Management Service level
[ ] No, please provide clinical rationale as to why the Client would benefit from a Pain Management service despite not meeting the eligibility requirements
**4. Triage report**
Description of the client's history
Include information on previous persistent pain, mental health conditions, substance misuse and any underlying conditions
**Injury history**
Hemi was injured on 14/10/2024 when his stationary taxi was struck from behind at traffic lights by a vehicle travelling approximately 40 km/h. He experienced immediate right-sided neck pain and right scapular pain, with delayed onset of intermittent right upper limb paraesthesia over the following 48 hours. The body region affected is the right cervical spine, upper trapezius, scapular region, and right upper limb. No loss of consciousness; no head strike. ACC-covered claim accepted for cervical whiplash.
**Pain history**
Pain duration is 19 months. Onset was acute and mechanical, initially well localised to the right paracervical and upper trapezius regions. Over the first 6 months the pain remained predominantly nociceptive in character. From approximately month 7 the pain progressively centralised, with widening of the affected area to involve the right interscapular region and intermittent radiation into the right forearm and hand. Current quality is aching with episodic sharp exacerbations and burning paraesthesia. Triggers include sustained driving, right cervical rotation, computer use, and lifting above 5 kg. Relieving factors include lying supine, heat, and tramadol.
**Previous persistent pain**
No prior history of persistent pain. Hemi reports an uncomplicated recovery from a left ankle fracture in 2011 (work-related, ACC) with no residual symptoms.
**Mental health history**
No formally diagnosed mental health conditions. Hemi describes a period of low mood approximately 8 years ago following the death of his father, managed within whānau without clinical intervention. He has no history of self-harm, suicidal ideation, or psychiatric admission. He has not previously engaged with psychological services.
**Substance use**
Alcohol use is social and within recommended limits, approximately 4 to 6 standard drinks per week. No illicit substance use. Tramadol is used as prescribed (see medication list); Hemi reports no escalation in self-administered dosing and is accepting of a structured taper as part of programme participation. Tobacco never used.
**Underlying conditions**
Type 2 diabetes (well controlled on metformin, HbA1c 52 mmol/mol at most recent reading 04/2026). Mild obstructive sleep apnoea (diagnosed 2023, declined CPAP). No inflammatory conditions. Clinical features consistent with central sensitisation are present and described in detail in the Summary of Findings below.
**Current treatments**
GP management with Dr Sue Patterson at Glen Eden Medical (regular reviews every 6 weeks). Community physiotherapy completed 12 weeks of treatment from 11/2024 to 02/2025 with limited functional gain; discharged. Two private sessions with a chiropractor 06/2025 to 07/2025 with no sustained benefit. Currently no allied health input. Tramadol initiated 02/2025 and continued since. No psychological input to date.
**Work and functional status**
Hemi is employed as a taxi driver with Tāmaki City Taxis. Pre-injury hours were 45 to 50 per week. He is currently working reduced hours of 20 to 25 per week on a flexible roster. His employer has been highly accommodating, allowing breaks and shift selection that minimises sustained head-turning. He reports difficulty with rear-vision tasks (head checks, reversing) which has reduced his comfort with night driving.
Summary of Findings
Include an evaluation of all possible causes and contributors to the pain/s. Describe the relationship between the pain the Client is experiencing, and the ACC covered injury. Include information about the Client's cultural considerations, values, and beliefs. This section should provide rationale for the recommended Pain Management Service in Section 3 and estimated timeframes of service.
Taha Tinana. Hemi presents 19 months after a clearly identifiable mechanical neck injury sustained in a rear-end motor vehicle collision, the ACC-covered event. His original injury produced a well-localised right cervical and scapular pain pattern. Over the second six months of recovery, the pain centralised and broadened, with development of allodynia to light pressure over the right paracervical muscles, mechanical hypersensitivity in the upper trapezius, and intermittent paraesthesia into the right upper limb without a corresponding dermatomal pattern. Imaging from 04/03/2025 demonstrated a mild C5-C6 disc bulge without cord or nerve root compression. There are no red flags. Useful cervical range remains (right rotation 50 degrees, left rotation 65 degrees) and shoulder function is preserved. The shift from clearly nociceptive pain in the first six months to widespread mechanical hypersensitivity over the last twelve months is consistent with central sensitisation. The relationship between the ACC-covered injury and the current presentation is complex: the original injury initiated the pain, but does not adequately account for its current distribution, severity, or persistence. He is maintained on tramadol with adjuncts; the duration and dose now warrant proactive opioid stewardship.
Taha Hinengaro. Hemi's emotional presentation is dominated by helplessness and a sense of lost agency over his pain, well reflected in his DASS-21 profile (Depression moderate, Stress moderate, Anxiety mild). His PCS profile is helplessness-dominant rather than rumination-dominant, suggesting a defeated stance toward recovery rather than a hyperalert scanning for danger. PSEQ at 22 out of 60 confirms low confidence in functioning despite pain and identifies this as the central modifiable barrier. He shows good insight, is help-seeking, and engaged constructively throughout the triage interview. Sleep is fragmented but does not meet criteria for a primary insomnia disorder.
Taha Wairua. Hemi's identity is deeply tied to his role as a provider for his whānau and as a working man in his community. The prolonged reduction in his work capacity has eroded that sense of purpose. He speaks with regret about no longer being the person his family relies on, and with frustration that he cannot enjoy activities that previously grounded him (touch rugby, hāngi preparation, gardening). He has not lost hope, but his hope is conditional on a path back to function. Being useful to whānau and community again is his stated primary motivator.
Taha Whānau. Hemi lives with his wife Ngaire and two adult children. His wife is supportive but reports feeling helpless watching him struggle; some relational strain exists around irritability and reduced participation in shared activities. His employer (Tāmaki City Taxis) has been accommodating, holding his role at reduced hours. He has retained close contact with his rugby club whānau even while not playing. The social environment is broadly supportive of recovery rather than reinforcing illness behaviour.
Whenua. Hemi self-identifies as Māori, with affiliations to Ngāti Porou (paternal) and Te Rarawa (maternal). He has consented to inclusion of his iwi affiliations in this report. He prefers English in clinical settings but values the use of te reo greetings and basic kupu where appropriate. He has indicated interest in connection with kaupapa Māori health resources during the programme and would welcome the option of a kaiāwhina or cultural support person at IDT review points. Cultural safety planning has been initiated at triage and will be confirmed at intake with the programme team.
Formulation. Hemi presents with a centralised pain syndrome maintained primarily by neurophysiological sensitisation, low pain self-efficacy, depressive mood and helplessness, and the long-term impact of opioid use. Without intervention, the trajectory is one of slow deconditioning, escalating opioid reliance, and progressive disengagement from work and identity-affirming activities. With intervention focused on graded reactivation, opioid tapering under medical oversight, cognitive-behavioural work targeting helplessness and self-efficacy, and culturally responsive engagement, his prognosis for functional gain is moderate to good. Community Services Level 2 is recommended on the basis of the multidimensional drivers, the opioid burden, and the requirement for combined medical and psychological input. Estimated programme duration is 16 weeks, with a midpoint IDT review at 8 weeks.
List of medicines
| Medication | Dose | Frequency | Prescribing Clinician | Notes |
|------------|------|-----------|----------------------|-------|
| Tramadol | 50 mg | Up to four times daily as required (averaging 150 to 200 mg per day) | Dr Sue Patterson, GP | OPIOID. 18 months continuous use. Tapering plan required as a programme priority. |
| Amitriptyline | 25 mg | Nightly | Dr Sue Patterson, GP | Adjuvant for neuropathic pain modulation and sleep. |
| Paracetamol | 1000 mg | Up to four times daily as required | Dr Sue Patterson, GP | Adjunctive analgesic; no concerns. |
| Diclofenac topical 1% gel | Pea-sized amount | Up to four times daily to neck and shoulder | Dr Sue Patterson, GP | Adjunctive; well tolerated. |
| Metformin | 1000 mg | Twice daily | Dr Sue Patterson, GP | For type 2 diabetes; not directly relevant to pain presentation. |
Summary of ePPOC results
Hemi's pre-triage ePPOC battery (completed 12/05/2026) describes a multidimensional pain experience consistent with chronic high-impact pain.
BPI: Pain severity composite of 6/10 and pain interference composite of 7/10 reflect substantial functional impact across daily activities, mobility, sleep, work, and enjoyment of life. The interference composite exceeding the severity composite is characteristic of central sensitisation presentations, where disability is driven more by the system's response to pain than by raw nociceptive input.
DASS-21: Depression 14 (Moderate), Anxiety 8 (Mild), Stress 18 (Moderate). The depression-stress signal is more elevated than the anxiety signal, painting a picture of grinding low mood and felt overload rather than acute worry. This is consistent with the helplessness-dominant pattern seen on the PCS and contextualises the impact of his prolonged time at reduced work hours.
PCS: Total 28 out of 52, placing Hemi in the moderate catastrophising range. The dominant subscale is Helplessness (12/24), with lower contributions from Rumination (9/16) and Magnification (7/12). The implication for programme engagement is that interventions targeting agency, self-efficacy, and small experiential wins will be more effective than interventions targeting attentional patterns alone.
PSEQ: 22 out of 60, reflecting low pain self-efficacy. Hemi does not currently believe he can do what matters to him while pain is present. This is the central modifiable barrier to functional recovery and the primary target for the cognitive-behavioural components of the programme.
Opioid flag: Hemi has been on tramadol for 18 months with an average daily dose in the 150 to 200 mg range. There are no current concerns about misuse, however the duration and dose warrant a structured tapering plan with medical oversight as a programme priority. Continued opioid use at this level is unlikely to be supporting his functional recovery and may be contributing to mood and cognitive flattening.
Date of Triage: 14/05/2026
Date of IDT Review: 21/05/2026
| Role | Name | Discipline |
|------|------|------------|
| Triage Clinician and IDT Member | Dr Ruth Coleman | Pain Medicine Specialist |
| IDT Member | Dr Toni Webb | Clinical Psychologist |
| IDT Member | Maia Henare | Physiotherapist |
**5. Declaration and signatures**
I certify that:
- I have personally examined and/or treated the client.
- I have discussed the recommendations I have made in this report and the rationale for these with the client and other provider/s who have performed the triage and case review.
- The client (or their representative) has authorised me to provide this information to ACC.
Name of Triage clinician: Dr Ruth Coleman
**Signature:**
**Date:** 22/05/2026
When we collect, use and store information, we comply with the Privacy Act 2020 and the Health Information Privacy Code 2020. For further details see ACC's privacy policy, available at [www.acc.co.nz](https://www.acc.co.nz). We use the information collected on this form to fulfil the requirements of the Accident Compensation Act 2001.
**Items for Clinician Review**
- Section 4, ePPOC scores: BPI severity composite stated verbally as "six out of ten" and interference as "seven out of ten"; verify both against the documented BPI questionnaire from 12/05/2026 before submission.
- Section 4, Iwi affiliation: Hemi consented during triage to inclusion of his Ngāti Porou and Te Rarawa affiliations in this report; confirm at IDT review that consent extends to sharing with the programme team and any kaupapa Māori health partners engaged during the service.
- Section 4, Tramadol average daily dose: stated as "150 to 200 milligrams per day"; confirm with Dr Sue Patterson's prescribing records and Hemi's recent dispensing data before submission.
**ACC7984**
**Pain Management Services Triage Report**
"Please complete this form to let us know about this client's triage assessment, the conclusions regarding the likely diagnosis/es and cause/s and the proposed clinical care pathway."
"When you've finished, please send a copy to the ACC recovery team member managing the Claim or to claims@acc.co.nz if you are unsure of the Recovery Team Member/Recovery Team."
**1. Client details**
Client name: [client's full name] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain section heading and lead-in, and leave blank)
Address: [client's residential address] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain lead-in, and leave blank)
Claim number: [client's ACC claim number] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain lead-in, and leave blank)
Date of birth: [client's date of birth] (Print the date in DD/MM/YYYY format. Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain lead-in, and leave blank)
**2. Vendor details**
Supplier name: [supplier/practice name] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain lead-in, and leave blank)
Vendor number: [vendor number] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain lead-in, and leave blank)
Phone number: [vendor phone number] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain lead-in, and leave blank)
Vendor email address: [vendor email address] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain lead-in, and leave blank)
**3. Confirmation of suitability for the Pain Management Service**
**Recommendation:**
"Note: Choose Group Programme when required, and/or one of the following Community Level 1, Community Level 2 or Tertiary if required"
"Rationale for any recommended Pain Management Service is provided in the Summary of Findings in Section 4."
[ ] Not suitable for a Pain Management service (see below) (Mark with '[x]' if the client is not suitable for a pain management service)
[ ] Group Programme (Mark with '[x]' if the client is recommended for the Group Programme)
[ ] Community Services Level 1 (Mark with '[x]' if recommended — only one of Community Level 1, Community Level 2, or Tertiary Delivery Services can be selected)
[ ] Community Services Level 2 (Mark with '[x]' if recommended — only one of Community Level 1, Community Level 2, or Tertiary Delivery Services can be selected)
[ ] Tertiary Delivery Services (Mark with '[x]' if recommended — only one of Community Level 1, Community Level 2, or Tertiary Delivery Services can be selected)
"If the client is not suitable for the Pain Management Service, please explain why and any recommendations on what support or alternative service the client needs:"
[explanation of why the client is not suitable and recommendations for alternative service or support] (Only include if Not suitable is marked '[x]'; else omit placeholder, retain lead-in, and leave blank)
"For clients who are recommended for the Pain Management Service, do they meet the eligibility criteria?"
[ ] Not applicable, the Pain Management Service is not recommended (Mark with '[x]' if the service is not recommended)
[ ] Yes, the client meets the eligibility criteria for the recommended Pain Management Service level (Mark with '[x]' if eligibility criteria are met)
[ ] No, please provide clinical rationale as to why the Client would benefit from a Pain Management service despite not meeting the eligibility requirements (Mark with '[x]' if criteria are not met but service is still warranted)
[clinical rationale for recommending service despite not meeting eligibility requirements] (Only include if No is marked '[x]'; else omit placeholder, retain lead-in, and leave blank)
**4. Triage report**
Description of the client's history
"Include information on previous persistent pain, mental health conditions, substance misuse and any underlying conditions"
**Injury history**
[description of the mechanism of injury, date of injury, and body region affected] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain subheading, and leave blank)
**Pain history**
[description of pain duration, onset pattern, quality and nature of pain, and any progression or spread over time] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain subheading, and leave blank)
**Previous persistent pain**
[description of any prior persistent pain episodes, relevant treatment history, and response to past interventions] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain subheading, and leave blank)
**Mental health history**
[description of diagnosed or suspected mental health conditions, including previous episodes of depression, anxiety, PTSD, or other relevant history] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain subheading, and leave blank)
**Substance use**
[description of current or historical use of alcohol, opioids, or other substances, using clinical and non-judgemental language] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain subheading, and leave blank)
**Underlying conditions**
[description of comorbidities relevant to the pain presentation, such as inflammatory conditions, sleep disorders, or features of central sensitisation] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain subheading, and leave blank)
**Current treatments**
[description of current medications, allied health input, and GP management] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain subheading, and leave blank)
**Work and functional status**
[description of current employment status, work capacity, any restrictions or modified duties in place] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain subheading, and leave blank)
Summary of Findings
"Include an evaluation of all possible causes and contributors to the pain/s. Describe the relationship between the pain the Client is experiencing, and the ACC covered injury. Include information about the Client's cultural considerations, values, and beliefs. This section should provide rationale for the recommended Pain Management Service in Section 3 and estimated timeframes of service."
[Write a flowing clinical narrative of approximately 350–500 words structured using the Te Whare Tapa Whā model. Do not use bullet points. Write in third person, using the client's first name where known. For each dimension, identify both what is going well (strengths, protective factors) and what needs attention (contributors to pain, barriers to recovery). Structure as follows:
Taha Tinana — Physical Wellbeing: Open the narrative here. Describe preserved physical function and capacity alongside injury background, pain characteristics (location, quality, spread, triggers, aggravating and relieving factors), functional limitations, physical examination findings, red flag status, and medication burden. Draw the relationship between the ACC-covered injury and the current pain presentation — is it clear, complex, or multifactorial?
Taha Hinengaro — Mental and Emotional Wellbeing: Transition naturally from the physical picture. Describe psychological strengths such as insight, motivation, or help-seeking behaviour, alongside challenges including mood, anxiety, cognitive patterns (catastrophising pattern from PCS, fear-avoidance beliefs), and how distress is interacting with or amplifying the pain experience. Interpret the DASS-21 findings as a picture of the person's emotional world — not a list of scores.
Taha Wairua — Spiritual Wellbeing: Address meaning, purpose, identity, and hope. Describe what sustains or grounds the client — their values, sources of meaning, resilience, or motivation for recovery — alongside what has been disrupted by the injury (loss of role, identity, hopelessness, or disconnection from purpose). Include cultural or spiritual beliefs about pain and healing if known.
Taha Whānau — Family and Social Wellbeing: Describe the social landscape, naming who supports the client (whānau, family, trusted relationships, workplace allies) alongside what needs attention (relationship strain, social isolation, work environment dynamics). Reflect on whether the social environment is reinforcing recovery or inadvertently maintaining avoidance or disability behaviour.
Whenua — Cultural Identity and Grounding: The whenua is the foundation the wharenui stands on. Describe the client's connection to identity, culture, place, and roots. Note cultural background, iwi or hapū affiliation if known and consented, language preferences, and any cultural considerations that should shape the treatment approach. If cultural information is not yet known, state clearly that cultural safety planning is pending and should be explored at intake. Never leave this dimension entirely blank.
Close with a formulation statement: what is primarily driving and maintaining the pain, the likely trajectory with and without intervention, the rationale for the recommended service level, and the estimated programme timeframe.] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain section heading and lead-in, and leave blank)
List of medicines
[list of all current medications. Print each medicine on its own line. Flag any opioid medications clearly with the word OPIOID in the notes column. Note any polypharmacy concerns. If no medications are reported, state "Nil reported."] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain heading, and leave blank)
| Medication | Dose | Frequency | Prescribing Clinician | Notes |
|---|---|---|---|---|
| [medication name] | [dose] | [frequency] | [prescriber] | [notes — flag OPIOID if applicable] |
Summary of ePPOC results
[Write a clinical narrative interpretation of the ePPOC outcome measures provided in the contextual notes. Do not simply restate scores — interpret what they mean for this person's function and recovery. Cover each measure:
BPI: Report pain severity composite and interference composite (0–10 each). Interpret functionally — what level of limitation do these scores suggest in daily life, mobility, sleep, and work capacity?
DASS-21: Report each subscale score and severity band (Normal / Mild / Moderate / Severe / Extremely Severe). Describe clinical significance — which domain is most elevated, and how is distress interacting with the pain experience?
PCS: Report total score (0–52) and identify the dominant subscale (Rumination, Magnification, or Helplessness). Interpret the catastrophising pattern and its implications for programme engagement.
PSEQ: Report total score (0–60). Interpret the client's confidence in managing function despite pain — active self-management or significant self-limiting behaviour?
Opioid flag: If opioids are present, note this and describe clinical implications for programme participation, dependence risk, and dose trajectory.] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain heading, and leave blank)
Date of Triage: [date of triage assessment] (Print the date in DD/MM/YYYY format. Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain lead-in, and leave blank)
Date of IDT Review: [date of interdisciplinary team review] (Print the date in DD/MM/YYYY format. Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain lead-in, and leave blank)
| Role | Name | Discipline |
|------|------|------------|
| [role, e.g. Triage Clinician, IDT Member] | [name] | [discipline] |
(Populate one row per clinician or IDT member involved in the triage. Include the triage clinician and all IDT members. Minimum IDT composition: psychology + medical. Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder rows, retain table headers, and leave blank)
**5. Declaration and signatures**
"I certify that:
- I have personally examined and/or treated the client.
- I have discussed the recommendations I have made in this report and the rationale for these with the client and other provider/s who have performed the triage and case review.
- The client (or their representative) has authorised me to provide this information to ACC."
Name of Triage clinician: [triage clinician's full name] (Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain lead-in, and leave blank)
**Signature:**
**Date:** [date of signature] (Print the date in DD/MM/YYYY format. Only include if explicitly mentioned in transcript, contextual notes or clinical note; else omit placeholder, retain lead-in, and leave blank)
"When we collect, use and store information, we comply with the Privacy Act 2020 and the Health Information Privacy Code 2020. For further details see ACC's privacy policy, available at www.acc.co.nz. We use the information collected on this form to fulfil the requirements of the Accident Compensation Act 2001."
**Items for Clinician Review**
[checklist of items requiring clinician verification before finalising and submitting to ACC. Print each flagged item on its own line beginning with '-' (bullet point), followed by the section name and a brief description of what needs verification. Flag anything where the clinician should check before sign-off, including: identity or demographic details that were unclear, partial, or potentially misheard (name spelling, claim number, date of birth, address); dates spoken partially or ambiguously (date of injury, triage date, IDT review date); mechanism of injury described vaguely or incompletely; diagnoses lacking specificity (no laterality, no chronicity, working diagnosis where definitive is expected); numerical values that were unclear or potentially misheard (pain scores, medication doses, ePPOC scores, ROM measurements); provider or vendor details not fully stated; opioid medications requiring prescriber confirmation; cultural considerations not yet explored or confirmed with the client; sections where expected information was not mentioned at all (consent, IDT composition, ePPOC scores); clinical content inferred from context rather than explicitly stated; conflicting information across the transcript, contextual notes, or clinical note; and abbreviations not clearly resolved. If no items require review, print "None flagged." Always include this section heading.]
(Always retain all section and sub-section headings in the output, regardless of whether content is available to populate them. If no information is explicitly mentioned for a given section or sub-section, leave the area beneath the heading blank but never remove the heading itself.)